Argos Therapeutics, an immuno-oncology company focused on the development of individualised immunotherapies, have published a Case Report in the Kidney Cancer Journal which details the clinical outcomes of two patients with intermediate risk metastatic renal cell carcinoma (RCC) who had participated in a Phase 2 clinical trial of AGS-003 in combination with sunitinib. These patients have obtained long-term control of metastatic RCC that is ongoing seven years after initiation of treatment. Analysis of follow-up data from the Phase 2 study showed a median overall survival of 61.9 months for patients with intermediate risk metastatic RCC, and an overall survival of 30.2 months for all patients.

AGS-003 is an individualised immunotherapy that uses the patient’s own immune cells from a sample of the patient’s tumour to induce a targeted immune response against the cancer. RNA is isolated from the tumour sample and used to programme immune cells to target disease-specific proteins. Activated immune cells are then mixed with the patient’s plasma, and administered via intradermal injection as an individualised immunotherapy.

AGS-003 is well-tolerated without significant additional side effects over sunitinib, and this investigational therapy remains promising for patients with advanced kidney cancer.

Read more here